Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


OxyPharma Initiates Phase II Clinical Trial of Its Oral Drug Rob 803 for Rheumatoid Arthritis

OxyPharma Initiates Phase II Clinical Trial of Its Oral Drug Rob 803 for Rheumatoid Arthritis

[Stockholm, Sweden, July 27, 2007.] Swedish drug development company OxyPharma today announced the initiation of its phase II clinical trial of Rob 803, the company’s orally administered compound for treatment of moderate or severe active Rheumatoid Arthritis (RA).

OxyPharma has received regulatory clearance to commence a phase II trial of its immunomodulator, Rob 803, in patients with moderate to severe active RA. OxyPharma expects to start enrollment of patients within a few days, starting in Latvia and Lithuania. The phase II study will be carried out in Belgium, Bulgaria, Latvia, Lithuania, Romania, Serbia, Sweden and the UK by Pharm-Olam International, a multi-national contract research organization. Principal Investigator is Prof. Lars Klareskog, Head of Rheumatology Unit at Karolinska Hospital, Stockholm, Sweden.

OxyPharma’s primary objective is to evaluate the clinical response rate of Rob 803 when added to a stable dose of methotrexate in 224 patients with moderate or severe active RA. Rob 803 will be given orally once daily for 12 weeks.

The placebo-controlled trial is intended to evaluate the compound’s tolerability, to determine the appropriate dosage and to provide laboratory results with indication of an anti-inflammatory effect of Rob 803. The trial is expected to be completed by March 2008.

OxyPharma’s phase I program to test the safety, tolerability and absorption of Rob 803 in healthy volunteers, demonstrated that Rob 803 was well tolerated with good oral absorption. These results support the move into the phase II program, an important milestone in OxyPharma’s drug's development program.

“The start of the first clinical trial in patients with our RA compound Rob 803 is a key milestone in the development of OxyPharma and our product portfolio”, said Ulf Björklund, CEO, OxyPharma.

There are presently no effective, safe and easily administrated drugs for the treatment of RA. The value of the global RA market is estimated at more than USD 3bn annually.

About OxyPharma:

OxyPharma is a Swedish drug development company developing new drugs primarily for the treatment of Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). The development programs are carried out in collaboration with the Karolinska Institute in Stockholm, Sweden and contract research organizations (CRO’s) in England, Sweden and Israel. OxyPharma was founded in 2002 and is based in Stockholm, Sweden. The company’s largest shareholder is innovator and entrepreneur Leif Lundblad (mainly through his investment company LLD Nybohov Invest). Ulf Björklund is OxyPharma’s CEO.

For additional information please contact:

Ulf Björklund
CEO, OxyPharma AB
Phone: +46 8 726 17 02 or +46 70 667 04 40


Peter Karaszi
Press Officer, OxyPharma AB
Phone: +27 83 243 57 97 or +46 70 341 46 53

Also see our web site:

Publisher Contact Information:

OxyPharma AB
+27 21 439 8806

Company profile of OxyPharma AB
Past press releases of OxyPharma AB.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 21€87.0MInternet services
Feb 21€18.0MInternet commerce
Feb 20€4.3MSoftware development
Feb 19€0.4MInternet commerce
Feb 19€8.4MMedical devices
Feb 18€25.0MBiotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.